Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Companyâs proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Companyâs segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
äŒæ¥ã³ãŒãPGEN
äŒç€ŸåPrecigen Inc
äžå Žæ¥Aug 08, 2013
æé«çµå¶è²¬ä»»è
ãCEOãSabzevari (Helen)
åŸæ¥å¡æ°143
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Aug 08
æ¬ç€Ÿæåšå°20374 Seneca Meadows Parkway
éœåžGERMANTOWN
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·20876
é»è©±çªå·13015569900
ãŠã§ããµã€ãhttps://precigen.com/
äŒæ¥ã³ãŒãPGEN
äžå Žæ¥Aug 08, 2013
æé«çµå¶è²¬ä»»è
ãCEOãSabzevari (Helen)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã